

Please type a plus sign (+) inside this box

PTO/SB/08A (09-00)

Approved for use through 10/31/2002, OMB 0951-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----------------------|---|------------------------|--|
| Substitute for form 1449A/PTO | | SEP 12 2003 | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | | 10/802,214 | |
| | | Filing Date | | 8/24/03 | |
| | | First Named Inventor | | Quan et al. | |
| | | Group Art Unit | | 1624 | |
| | | Examiner Name | | Unknown T. TRUONG | |
| Sheet | 1 | of | 2 | Attorney Docket Number | |
| | | | | DM-8904 CNT 2 | |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| TNT | ✓ | 5,202,330 | A | E. R. Squibb & Sons, Inc. | 4/13/1993 | 514/274 |
| | ✓ | 5,317,103 | A | Merck Sharp & Dohme Limited | 5/31/1994 | 544/367 |
| | ✓ | 5,342,851 | A | McNeil-PPC, Inc. | 8/30/1994 | 514/370 |
| | ✓ | 5,463,071 | A | Dr. Karl Thomae GmbH | 10/31/1995 | 548/281 |
| | ✓ | 5,816,601 | A | GD Searle & Co | 4/1/1997 | 514/399 |
| | ✓ | 5,681,838 | A | Hoechst AG | 10/28/1997 | 514/307 |
| | ✓ | 5,707,998 | A | Eisai Co., Ltd. | 1/13/1998 | 514/259 |
| | ✓ | 6,020,357 | A | DuPont Pharma. Company | 2/1/2000 | 514/406 |
| TNT | ✓ | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₀ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| TNT | ✓ | WO | 9402477 | A | Merck Sharp & Dohme Limited | 2/3/1994 | | |
| TNT | ✓ | WO | 9514683 | A | DuPont Merck Pharma. Company | 6/1/1995 | | |
| | ✓ | WO | 9518111 | A | DuPont Merck Pharma. Company | 7/6/1995 | | |
| | ✓ | WO | 9628427 | A | Berlex Lab., Inc. | 9/19/1996 | | |
| | ✓ | WO | 9640143 | A | SmithKline Beecham Corporation | 12/19/1996 | | |
| | ✓ | WO | 9723212 | A | DuPont Merck Pharma. Company | 7/3/1997 | | |
| TNT | ✓ | WO | 9732583 | A | SmithKline Beecham Corporation | 9/12/1997 | | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 7/28/05 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0091
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SEP 12 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/602,214 |
| Filing Date | 6/24/03 |
| First Named Inventor | Quan tal. |
| Group Art Unit | 1624 |
| Examiner Name | Unknown T. TRUONG |
| Attorney Docket Number | DM-6904 CNT 2 |

Sheet 2 of 2

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document ² | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₃ |
|--------------------|-----------------------|--------------------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| TNT | ✓ | EP | 234830 | A | E. R. Squibb & Sons, Inc. | 9/2/1987 | | |
| | ✓ | EP | 236902 | A | E. R. Squibb & Sons, Inc. | 9/16/1987 | | |
| | ✓ | EP | 513387 | B | Otsuka Pharm. Co. | 11/19/1992 | | |
| | ✓ | EP | 554829 | A | Fujisawa Pharm. Co. | 8/11/1993 | | |
| TNT | ✓ | JP | 4247081 | A | Takeda Chem. Ind. Ltd. | 9/3/1992 | Chemical Abstract | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| TNT | ✓ | TIDWELL et al. "Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases". J. Med. Chem. (1978), 21(7), 613-623. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>W. L. Wong</i> | Date Considered | 7/28/05 |
|--------------------|-------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SEP 12 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/602,214 |
| Filing Date | 6/24/03 |
| First Named Inventor | Quan et al. |
| Group Art Unit | |
| Examiner Name | Unknown |
| Attorney Docket Number | DM-6904 CNT 2 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | 5,202,330 | A | E. R. Squibb & Sons, Inc. | 4/13/1993 | |
| | | 5,317,103 | A | Merck Sharp & Dohme Limited | 5/31/1994 | |
| | | 5,342,851 | A | McNeil-PPC, Inc. | 8/30/1994 | |
| | | 5,463,071 | A | Dr. Karl Thomae GmbH | 10/31/1995 | |
| | | 5,616,601 | A | GD Searle & Co | 4/1/1997 | |
| | | 5,681,838 | A | Hoechst AG | 10/28/1997 | |
| | | 5,707,998 | A | Eisai Co., Ltd. | 1/13/1998 | |
| | | 6,020,357 | A | DuPont Pharma. Company | 2/1/2000 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₆ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | WO | 9402477 | A | Merck Sharp & Dohme Limited | 2/3/1994 | | |
| | | WO | 9514683 | A | DuPont Merck Pharma. Company | 6/1/1995 | | |
| | | WO | 9518111 | A | DuPont Merck Pharma. Company | 7/6/1995 | | |
| | | WO | 9628427 | A | Berlex Lab., Inc. | 9/19/1996 | | |
| | | WO | 9640143 | A | SmithKline Beecham Corporation | 12/19/1996 | | |
| | | WO | 9723212 | A | DuPont Merck Pharma. Company | 7/3/1997 | | |
| | | WO | 9732583 | A | SmithKline Beecham Corporation | 9/12/1997 | | |

Examiner Signature

Date Considered

7/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SEP 12 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number 10/602,214
Filing Date 6/24/03
First Named Inventor Quan et al.
Group Art Unit 1624
Examiner Name Unknown
Attorney Docket Number DM-6904 CNT 2

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₆ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | EP | 234830 | A | E. R. Squibb & Sons, Inc. | 9/2/1987 | | |
| | | EP | 236902 | A | E. R. Squibb & Sons, Inc. | 9/16/1987 | | |
| | | EP | 513387 | B | Otsuka Pharm. Co. | 11/19/1992 | | |
| | | EP | 554829 | A | Fujisawa Pharm. Co. | 8/11/1993 | | |
| | | JP | 4247081 | A | Takeda Chem. Ind. Ltd. | 9/3/1992 | Chemical Abstract | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | | TIDWELL et al. "Diarylamine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring, inhibitors of arginine-specific esterproteases". J. Med. Chem. (1978), 21(7), 613-623. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner Signature

[Signature]

Date Considered

7/28/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.